← Back to Search

Reminders for Shingles Vaccination

N/A

Recruiting

Led By Christopher F Chabris, PhD

Research Sponsored by Geisinger Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up in the 14 months following enrollment

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to see if sending messages to patients to ask about the Shingrix vaccine will help increase vaccination rates. They will also determine which message version works the best.

Who is the study for?

This trial is for individuals aged 50 or older who haven't had the Shingrix vaccine and have an upcoming non-urgent in-person appointment at a Geisinger primary care facility that has the vaccine available.

What is being tested?

The study is examining if different types of reminder messages can encourage patients to discuss and potentially receive the Shingrix shingles vaccine during their next doctor's visit.

What are the potential side effects?

Since this trial involves only reminder messages, there are no direct medical side effects. However, participants may experience increased awareness or anxiety about vaccination.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ in the 14 months following enrollment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~in the 14 months following enrollment

This trial's timeline: 3 weeks for screening, Varies for treatment, and in the 14 months following enrollment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Other study objectives

Attended scheduled appointment

Completion of Shingrix series

First Shingrix vaccination

+3 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

5Treatment groups

Experimental Treatment

Active Control

Group I: Multi-factExperimental Treatment1 Intervention

Patients in this arm will be sent messages with facts about shingles and Shingrix, and encouraging them to ask about Shingrix at their upcoming appointment.

Group II: High risk + multi-factExperimental Treatment1 Intervention

Patients in this arm will be sent messages informing them that they are at high risk for shingles because they are ages 50+, with additional facts about shingles and Shingrix, and encouraging them to ask about Shingrix at their upcoming appointment.

Group III: High riskExperimental Treatment1 Intervention

Patients in this arm will be sent messages informing them that they are at high risk for shingles because they are ages 50+, and encouraging them to ask about Shingrix at their upcoming appointment.

Group IV: Passive controlActive Control1 Intervention

Patients in this arm will not be sent any messages.

Group V: Active controlActive Control1 Intervention

Patients in this arm will be sent messages encouraging them to ask about Shingrix at their upcoming appointment.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Reminder

2023

Completed Early Phase 1

~311310